Abstract
-
▲ Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation.
-
▲ Dabigatran etexilate pharmacokinetics were linear across a wide dosage range. There were no clinically important pharmacokinetic interactions with digoxin (a P-glycoprotein substrate), pantoprazole (a proton-pump inhibitor) or drugs that are substrates and/or inhibitors of hepatic cytochrome P450 enzymes.
-
▲ In two large, randomized, double-blind trials of the prevention of venous thromboembolism (VTE) in patients undergoing total hip or total knee replacement surgery, orally administered dabigatran etexilate 220 mg/day was noninferior to subcutaneous enoxaparin sodium 40 mg/day for the primary composite endpoint of total VTE events or all-cause mortality during the treatment period.
-
▲ There were no significant differences between dabigatran etexilate and enoxaparin sodium in major VTE events and VTE-related mortality. Across trials, ≤0.5% of patients experienced a symptomatic pulmonary embolus or died.
-
▲ Dabigatran etexilate was generally well tolerated. In patients undergoing total hip or total knee replacement surgery, there was no significant difference between dabigatran etexilate and enoxaparin sodium recipients in the incidence of major or minor bleeding.
Similar content being viewed by others
Notes
The use of trade names is for identification purposes only and does not imply endorsement.
References
National Collaborating Centre for Acute Care. National Institute for Health and Clinical Excellence clinical guideline 46: venous thromboembolism. Reducing the risk of venous thrombo-embolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery [online]. Available from URL: http://www.nice.org.uk/Guidance/CG46 [Accessed 2008 May 13]
Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004; 64(6): 577–95
Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 Suppl. 3: 265–86s
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 Suppl. 3: 3338–4005s
Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005 Aug; 3(8): 1843–53
Boehringer Ingelheim Limited. Pradaxa: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2008 May 15]
Wienen W, Stassen J-M, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007 Jul; 98(1): 155–62
van Ryn J, Hauel N, Waldmann L, et al. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin [abstract no. 3998]. Blood 2007; 110(11): 68B
van Ryn J, Kink-Eiband M, Hauel N et al. Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma [abstract no. 1884]. Blood 2007; 110(11): 558a. Plus poster presented at the 49th Meeting of the American Society of Hematology; 2007 Dec 8–11; Atlanta (GA)
Liesenfeld K-H, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62(5): 527–37
Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 Sep; 64(3): 292–303
Stangier J, Stahle H, Rathgen K. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008 Jan; 47(1): 47–59
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47(5): 285–95
Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2(9): 1573–80
Stangier J, Eriksson BI, Dahl OE. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45(5): 555–63
Stangier J, Rathgen K, Stahle H, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate in subjects with moderate hepatic impairment [abstract no. P-W-673]. J Thromb Haemost 2007 Aug 6; 5 Suppl. 2
Troconiz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007 Mar; 47(3): 371–82
Stangier J, Stahle H, Rathgen K. Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects [abstract no.1612]. J Thromb Haemost 2005; 3 Suppl. 1
Eriksson BI, Dahl OE, Rosencher N. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5(11): 2178–85
The RE-MOBILIZE writing committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. Epub 2008 Apr 14
European Medicines Agency. CHMP assessment report for Pradaxa. London: European Medicines Agency, 2008; EMEA/174363/2008: 36
Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3(1): 103–11
UK Department of Health. Report of the independent expert working group on the prevention of venous thromboembolism in hospitalised patients [online]. Available from URL: http://www.thrombosis-charity.org.uk/cms/images/stories/File/reports/Report%20of%20the%20Expert%20Group%202007.pdf [Accessed 2008 Jun 26]
Acknowledgements and Disclosures
The manuscript was reviewed by: D. Bergqvist, Department of Surgery, University Hospital, Kir Kliniken Uppsala, Akademiska Sjukhus, Uppsala, Sweden; A.W. Fox, University of California San Diego and EBD Consulting, Carlsbad, California, USA; B.B. Jilma, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from any comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sanford, M., Plosker, G.L. Dabigatran Etexilate. Drugs 68, 1699–1709 (2008). https://doi.org/10.2165/00003495-200868120-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200868120-00007